Vessel Wall Biology, Atherosclerosis, Intimal Hyperplasia, Ischemia-Reperfusion, and Aneurysm Biology

3.1Biological foundations of atherosclerosis

Atherosclerosis is an inflammatory, thrombotic, and structural disease of the arterial wall. Plaque formation is driven by endothelial injury, lipid-driven inflammation, extracellular remodeling, smooth-muscle-cell plasticity, and thrombosis Inflammation in Atherosclerosis 2024 · Libby 2019. Plaque morphology progresses through pathologic intimal thickening, fibroatheroma, thin-cap fibroatheroma, and ultimately rupture, erosion, or calcified-nodule patterns Virmani 2000. Acute thrombotic events occur when structural plaque features, particularly rupture or erosion, expose subendothelial biology to circulating blood Libby 2013 · Falk 1995.

3.2Aneurysm biology and progression

An aneurysm represents a biologically active wall failure characterized by extracellular-matrix degradation, elastin loss, inflammatory infiltration, and smooth-muscle-cell apoptosis Role of ECM and Inflammation in AAA 2022. Wall degeneration is mediated by proteolysis, including macrophage elastase and matrix metalloproteinases (MMP-2, MMP-9), creating a progressive, asymmetric failure phenotype UK Small Aneurysm Trial 2002 · Curci 1998.

Because validated biological markers are not yet available for routine clinical use, management frameworks rely on maximum diameter as a proxy for wall failure ESVS 2024 · AHA 2022 · USPSTF 2019 · SVS 2018. In abdominal aortic aneurysm surveillance, average growth rates are approximately 2 to 3 mm/year for aneurysms measuring 3.0 to 3.9 cm, and 3 to 4 mm/year for those measuring 5.0 to 5.5 cm. Growth accelerates in a non-linear fashion as baseline diameter increases UK Small Aneurysm Trial 2002.

3.3Intimal hyperplasia and restenosis

Intimal hyperplasia is a regulated injury response following angioplasty, stenting, bypass, and dialysis access creation Phenotypic Switching 2025 · Allahverdian 2021. Normal adult arterial vascular smooth-muscle cells maintain a contractile phenotype, expressing markers such as SM-MHC, SM22-alpha, alpha-SMA, and calponin. In response to mechanical injury, hemodynamic stress, or atherosclerosis, these cells undergo a phenotypic switch to synthetic, proliferative, macrophage-like, osteogenic, or mesenchymal states.

Vein grafts exposed to the arterial pressure and flow environment undergo analogous smooth-muscle-cell phenotypic switching during adaptation, driving intimal hyperplasia Phenotypic Switching 2025. This cellular plasticity dictates that a morphologically excellent procedural result remains vulnerable to late failure, requiring protocol-driven duplex surveillance and reintervention planning Allahverdian 2021.

3.4Ischemia-reperfusion and organ injury

Revascularization restores oxygenated flow but initiates a secondary phase of tissue damage known as ischemia-reperfusion injury. The process is biphasic:

• Ischemic phase: Characterized by ATP depletion, lactate accumulation, ionic dysregulation, and hypoxia-inducible factor activation.
• Reperfusion phase: Driven by reactive oxygen species generation, complement activation, neutrophil-endothelial adhesion, microvascular vasoconstriction, and calcium overload.

This mechanism amplifies tissue injury despite macroscopic vessel patency, precipitating edema, microvascular no-reflow, systemic inflammation, and target-organ dysfunction StatPearls Reperfusion 2023 · Hausenloy 2013 · Eltzschig 2011. Clinical management relies on active postoperative physiological surveillance, monitoring for compartment syndrome, acute kidney injury, lactic acidosis, and arrhythmias.

3.5Medical management and biological modulation

Systemic medical therapy modifies the active biology of the vessel wall and reduces cardiovascular events across the entire arterial tree. Lipid-lowering therapy serves as the cornerstone of plaque stabilization and event reduction. In the REACH registry of approximately 5,800 symptomatic peripheral artery disease patients followed for 4 years, statin therapy was associated with a reduction in major adverse cardiovascular events to 14% compared to 22% in patients not receiving statins, yielding an adjusted hazard ratio of 0.83 REACH Registry 2014. Symptomatic peripheral artery disease is a very-high-risk category, so the LDL-C target is below 1.4 mmol/L (55 mg/dL) together with at least a 50% reduction from baseline ESC 2019. When LDL-C remains at or above 1.8 mmol/L (70 mg/dL) on maximally tolerated statin, add ezetimibe and then a PCSK9 inhibitor ACC/AHA 2018.

3.6Areas of controversy

Several areas of vessel-wall biology and targeted management remain unsettled in clinical practice:

• Anti-inflammatory therapy in peripheral vascular disease: While the CANTOS, COLCOT, and LoDoCo2 trials established the efficacy of modulating vascular inflammation with agents such as canakinumab and low-dose colchicine in coronary disease, routine anti-inflammatory prescribing for peripheral vascular-surgery populations is not fully established LoDoCo2 (2020) · COLCOT (2019) · CANTOS (2017). In CANTOS (roughly 10,000 patients randomised), canakinumab lowered the primary cardiovascular composite (hazard ratio about 0.85) but increased fatal infection and is not approved for a cardiovascular indication, so anti-inflammatory therapy remains investigational for peripheral vascular disease.
• Ischemia-reperfusion interventions: Pharmacologic and physical interventions targeting ischemia-reperfusion pathways have consistently failed translation into clinical benefit. In the ERICCA trial, remote ischemic conditioning showed no benefit on 12-month composite cardiovascular outcomes in cardiac surgery despite strong mechanistic plausibility ERICCA (2015).
• Advanced plaque imaging: Positron emission tomography and high-resolution magnetic resonance imaging can identify active vascular inflammation, but their role in directing surgical intervention over standard anatomic and symptomatic criteria remains investigational Advances in Clinical Imaging 2024.
• Biomarker-based aneurysm thresholds: Management continues to rely on anatomic diameter rather than circulating or imaging markers of extracellular matrix degradation, as biological markers are not yet validated to supersede dimensional criteria Role of ECM and Inflammation in AAA 2022 · UK Small Aneurysm Trial 2002.